logo

Zymeworks Inc. (ZYME)



Trade ZYME now with
  Date
  Headline
10/16/2019 4:23:16 PM Zymeworks Appoints Kathryn O’Driscoll As Chief People Officer
9/17/2019 6:57:32 AM Zymeworks Names Lota Zoth Chair Of Board; To Voluntarily Delist From TSX
6/19/2019 9:35:07 PM Zymeworks Announces Pricing Of $175.0 Mln Public Offering
5/29/2019 6:55:41 AM Zymeworks To Get $2.0 Mln In Connection With Merck’s Completion Of Preclinical Study For Bispecific Antibody Candidate
4/15/2019 6:49:20 AM Zymeworks Initiates Multicenter Phase 2 Clinical Trial On ZW25
1/17/2019 5:03:10 PM Zymeworks Reports Second IND-Submission Milestone Achieved In Lilly Collaboration
11/27/2018 6:34:36 AM Zymeworks And BeiGene Announce License Deal For Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 And ZW49
10/23/2018 8:55:40 AM Zymeworks, LEO Pharma Enter Bispecific Antibody Licensing And Research Collaboration
10/23/2018 6:50:00 AM Zymeworks And LEO Pharma A/S Enter Licensing And Research Collaboration
8/1/2018 8:07:50 AM Zymeworks Q2 Revenue $22.0 Mln Vs. $1.3 Mln Prior Year
6/11/2018 9:37:12 AM Zymeworks Closes Public Offering Of 6.21 Mln Shares
4/25/2018 6:10:29 AM Zymeworks Reports Selection Of ZW25 Abstract For Oral Presentation At ASCO Annual Meeting
4/17/2018 5:35:03 AM Zymeworks Presents Preclinical Data On ZW49; Expects To File IND Application This Year
3/29/2018 6:33:10 AM In The Spotlight: Zymeworks
  
 
>